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ABSTRACT  
The intent of this research was to formulate and evaluate controlled release ocusert of sulfacetamide sodium for the treatment of bacterial 
conjunctivitis. Ocusert is a sterile preparation having drug as dispersion or as solution in the polymeric base. Prepared Ocuserts were 
formulated using hydroxyl propyl methyl cellulose K-15 and Ethyl cellulose as polymers at various concentrations and combinations. Polymeric 
Films were prepared by mercury casting method using different ratios of polymers. Selected physiochemical properties such as thickness, 
weight, percentage moisture absorption, and in-vitro release and sterility studies of sulfacetamide sodium ocusert were studied and reported 
that prepared ocusert resolved the problems of poor bioavailability, frequent dosing and wastage of active ingredient.  
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INTRODUCTION 
The human eye is a body part that reacts to light. As a sense 
organ, the mammalian eye allows vision, perception and 
vision including colour differentiation and the perception of 
depth1. The main purpose of formulating ocusert is to 
enhance ocular bioavailability by increasing the corneal 
contact time. Fewer administrations provide patient 
compliance. Bacterial conjunctivitis or pink eye is a common, 
self-limiting condition that is typically caused by 
adenovirus2.  
Topical application of drug to the eye is the most popular and 
well-accepted root of administration for the treatment of 
various eye disorders. The bioavailability of ophthalmic drug 
is, however, very poor due to efficient protective 
mechanisms of the eye3. Many ophthalmic drug delivery 
systems are available these are classified as conventional and 
non-conventional (newer) drug delivery systems. Most 
commonly available ophthalmic preparations are eye drops 
and eye ointments which are instilled into the cal-de-sac are 
rapidly drained away from the ocular cavity due to tear flow 
and lachrymal nasal drainage4. The release of the drug from 
such a system is the consequence of the contact of the device 
with the tear fluid inducing a superficial diversion of the 
matrix5. 
Ocusert is the delivery system which is determined for its 
most logical aspects. The main objective of this delivery 
system is the increased residence time in the eye. This 
delivery system is the preferred route to deliver the drug as 
it provides sustained and controlled release of the drug to 
the desired site of action6. 
Sulfacetamide sodium is a sulphonamide antibiotic with 
inhibitive activity towards bacteria and broad-spectrum 
activity towards most gram-positive and many gram-
negative bacteria’s7. It is used for the treatment of bacterial 
conjunctivitis and other superficial ocular infections due to 
susceptible Escherichia coli, Staphylococcus aureus, 
Streptococcus pneumoniae, Streptococcus (viridans group), 
Haemophilus influenzae, Klebsiella species, Enterobacter 
species8. However, many strains of different species might be 
resistant9. Wide distribution of sulphonamides is observed 
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throughout the body. Enhanced levels are achieved in 
synovial, pleural, ocular and peritoneal fluids10. 
Sulphonamides act as competitive inhibitors of p-amino 
benzoic acid in the metabolism cycle of folic acid11. The 
inhibition process is obligatory in these organisms for the 
production of folic acid.  
MATERIALS AND METHODS 
Sulfacetamide sodium was procured from Ramson Remedies 
Pvt. Ltd., Amritsar (Punjab). PVA, HPMC and di-butyl 
phthalate were purchased from Sigma Aldrich. Chloroform 
and hydrochloric acid were purchased from Merk. All 
chemicals were of analytical grade. 
Preparation of ocuserts 
Ocusert of sulfacetamide sodium was prepared in following 
three steps-  
i. Preparation of the drug reservoir,  
ii. Preparation of the rate controlling membrane and  
iii. Sealing of the rate controlling membranes with the 
reservoir. 
i. Preparation of the drug reservoir 
The Sulfacetamide sodium ocular inserts were prepared by 
solvent casting method. The required quantity of polymer 
and plasticizer were weighed and dissolved in double 
distilled water (20 ml) and the mixture was heated at 60°C 
on a water bath until the entire polymer was dissolved. The 
drug material was calculated mathematically as per clinical 
dose. Weighed amount of Sulfacetamide sodium (# 400) was 
added and stirred for 6 hours at 40°C on magnetic stirrer to 
get uniform dispersion. The solution was sonicated until 
uniformity was obtained. After complete mixing, the casting 
solution (1 ml) were poured into glass rings (8 mm) which 
were lying on the mercury as substrate in the petri-dish and 
then placed in the hot air oven for 48 hours at 40ºC. The 
petri-dish was covered with inverted funnel to ensure the 
slow evaporation of solvent. The dried films were then 
separated from glass rings carefully with the help of surgical 
blade. The prepared reservoirs were then stored in 
desiccators under ambient condition4.  
Preparation of the rate controlling membranes 
A weighed quantity of polymer was dissolved in 5 ml of 
ethanol to obtain polymeric solution. Stirring was 
continuously maintained until the clear solution was 
obtained. These solutions were poured into glass ring (8 
mm) which was lying on the mercury as substrate in the 
petri-dish and then remaining solution (2 ml) was placed in 
the hot air oven for 48 hours at 40ºC. The dried films were 
removed as separated earlier12. 
Sealing of the films 
The drug reservoir was sandwiched in between the two rate 
controlling membranes and sealing was done by applying 
chloroform on the edges of the rate controlling membrane so 
that both the sides of the drug reservoir were sealed to 
control the release from periphery. The ocular inserts were 
stored in an air tight container13. 
 
 
Table 1: Composition of the reservoir films 
S. No. Ingredients F1A F2A F3A F4A 
1 Sulfacetamide sodium (mg) 20 20 20 20 
2 Polyvinyl alcohol (PVA)  0.6% 0.7% 0.8% 0.9% 
3 Hydroxypropyl methyl cellulose K-15(HPMC K-15) 0.6% 0.7% 0.8% 0.9% 
4 Dibutyl phthalate (% w/w of polymer) 30% 30% 30% 30% 
5 Double distilled water (ml)  15 15 15 15 
 
Table 2: Composition of rate controlling membranes 
S. No. Ingredient F1B F2B F3B F4B 
1 Ethyl cellulose  1.2% 1.4% 1.6% 1.8% 
3 Dibutyl phthalate (% w/w of polymer) 30% 30% 30% 30% 
4 Ethanol (ml) 15 15 15 15 
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Table 3: Final formulations prepared after sealing: 
Formulations Drug reservoir + rate 
controlling membrane 
F1 F1A + F1B 
F2 F1A + F2B 
F3 F1A + F3B 
F4 F1A + F4B 
F5 F2A + F1B 
F6 F2A + F2B 
F7 F2A + F3B 
F8 F2A + F4B 
F9 F3A + F1B 
F10 F3A + F2B 
F11 F3A + F3B 
F12 F3A + F4B 
F13 F4A + F1B 
F14 F4A + F2B 
F15 F4A + F3B 
F16 F4A + F4B 
 
Characterization of ocular inserts of Sulfacetamide 
sodium 
Physical evaluation  
Ocusert film was evaluated for physical evaluations such as 
properties, shape, colour, texture and appearance14.  
Uniformity of thickness 
The thickness of the insert was determined using a 
Micrometre screw gauge. Three randomly selected inserts 
were tested for their thickness at five separate points of each 
inserts for each formulation15. 
Uniformity of weight 
Ocular insert was weighed individually using digital balance. 
The mean weight of the insert was noted16. 
Drug content 
The ocusert from each formulation was dissolved or crushed 
in 10 ml of isotonic phosphate buffer (pH 7.4) in a beaker 
and were filtered into 25 ml volumetric flask and the volume 
was made up to the mark with buffer. One ml of the sample 
was withdrawn and the absorbance was measured by UV-
Visible spectrophotometer at 271 nm after suitable 
dilutions17. 
% Moisture absorption  
This was done to check the physical stability or integrity of 
the films at humid condition. The films were weighed and 
placed in desiccators containing 100 ml of saturated solution 
of aluminium chloride and 80% humidity was maintained. 
After three days the films were taken out and reweighed18. 
The % moisture absorption was calculated using the 
formulae: 
% Moisture absorption = 
Final weight – Initial weight  
× 100 
Initial weight 
% Moisture Loss  
This was carried out to check the integrity of the films in dry 
condition. The films were weighed and kept in desiccators 
containing anhydrous calcium chloride19.  
Folding endurance 
Folding endurance was determined by repeatedly folding a 
small strip of the film at the same place till it broke. The 
number of times the film could be folded at the same place 
without breaking gave the value of folding endurance. A 
mean of three readings were recorded20. 
Surface pH 
The inserts were allowed to swell in closed petri dish at 
room temperature for 30 min in 0.1 ml of double distilled 
water and placed under digital pH meter to determine the 
surface pH. The pH meter was calibrated before each use 
with standard pH 4 and 7 buffer solutions21. 
Swelling index 
Three ocuserts were weighted and placed separately in 
beakers 4 ml of simulated tear fluid. After a period of 5 
minutes, ocuserts were removed and the excess water on the 
ocuserts was wiped and weighed22. The % swelling index 
was calculated as: 
(Weight of swollen insert after time – original weight of 
insert at zero time) × 100 
In vitro diffusion study 
In-vitro release studies were carried out using bi-chambered 
donor receiver compartment model (Franz diffusion cell). 
The diffusion cell membrane (pre-hydrated cellophane) was 
tied to one end of the open cylinder, which acted as donor 
compartment. The ocular insert was placed on a dialysis 
membrane which was in contact with receptor medium 
comprising of 22 ml of STF (pH=7.4). The content of the 
receptor compartment was stirred continuously using a 
magnetic stirrer and temperature was maintained at 370± 
0.50C. The receptor medium was stirred continuously at 
20rpm to simulate blinking action of eyelids. At specific time 
interval, 1ml aliquot of the solution was withdrawn and 
replaced with fresh STF and required dilutions were made. 
The aliquot was analysed for drug content was analysed 
using UV Spectrophotometer at 256 nm against reference 
standard using simulated tear fluid as blank23. 
Mechanism and kinetics of drug release from an 
ophthalmic insert 
In order to understand the mechanism and kinetics of drug 
release, the results of in vitro drug release study were fitted 
with various kinetic equations like zero order (%drug 
release vs. time), first order (log% unreleased vs. time), and 
Higuchi matrix (% release vs. square root of time)24. 
Sterility studies   
All ophthalmic preparations should be sterile therefore the 
test for sterility is very important evaluation parameter. The 
sterility test was performed according to Indian 
Pharmacopoeia. Direct inoculation method was used 2 ml of 
prepared Sulfacetamide sodium ocusert solution was 
removed with a sterile pipette or with a sterile syringe or a 
needle. The test liquid was aseptically transferred to fluid 
thioglycolate medium and soyabean-casein digest medium 
separately. The liquid was mixed with the media. The 
inoculated media were incubated for not less than 14 days at 
30°C to 35°C in the case of fluid thioglycolate medium and 
20°C to 25°C in the case of soyabean-casein digest medium25. 
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RESULTS  
Physical evaluation 
Table 4: Physical evaluation of prepared ocusert 
Properties Results observed 
Shape Circle 
Colour White 
Appearance Uniform (no visible cracks) 
Texture Smooth 
 
Uniformity of thickness 
The average thickness of Ocuserts was between 0.12 
±0.013mm to 0.19±0.072mm. There were no marked 
variations in the thickness of Ocuserts within each 
formulation indicating uniform behaviour of film throughout 
the process. 
Uniformity of Weight 
The average weights of Ocuserts were found to be in the 
range of 6.1 mg to 7.2 mg. The uniformity of weight of 
Ocusert indicated good distribution of the drug, polymer and 
plasticizer. 
Swelling Index 
The polyvinyl alcohol (PVA) and Hydroxypropyl methyl 
cellulose (HPMC) are hydrophilic polymers and are soluble 
in water. Due to hydrophilic nature of PVA and HPMC it was 
expected to absorb water. Because of this swelling index test 
was carried out. The result showed that there was no 
significant variation in the water absorbs properties of 
formulations.  Swelling index was found in the range of 1.45 
to 2.80%. 
Folding Endurance 
The folding endurance was measured for all formulations 
manually. It was found in the range of 77 to 98. This test 
reflects the flexibility of ocuserts. This test ensures that the 
prepared ocuserts were suitable for large scale manufacture 
to produce long, continuous film without breaking or tearing. 
% Moisture absorption 
The % moisture absorption was calculated for all 16 
formulations. A positive linear correlation was found 
between the moisture absorption capacity and the 
concentration of hydrophilic polymers PVA and HPMC 
increased the % moisture absorption also increased. 
% Moisture loss 
The % moisture loss was calculated for all 16 formulations. A 
positive linear correlation was found between the moisture 
absorption capacity and the concentration of hydrophilic 
polymers PVA and HPMC increased the % moisture loss also 
decreased. 
Surface pH 
The prepared ocular insert was subjected for measurement 
of pH and it was found in range of 6.8 to 7.20. The pH range 
of all the formulation was found near to tear fluid pH so 
patient compliance of ocular insert is good. 
Drug content 
The Drug content was found consistent in all formulations 
and varied from 91.45 ±0.02% and 99.78±0.01%.
 
Table 1: Evaluation chart of ocusert 
Formulation 
code 
Weight 
(mg) 
Thickness 
(mm) 
Surface 
pH 
Folding 
Endurance 
%Moisture 
absorption 
%Moisture 
loss 
Swelling 
Index (%) 
Drug 
Content 
F1 6.49±0.12 0.11±0.004 7.10±0.07 77±2.17 5.23±0.23 8.35±0.30 1.84±0.0108 91.45±0.02 
F2 6.91±0.21 0.129±0.009 6.87±0.13 79±1.92 5.81±0.35 9.4±0.23 1.67±0.0211 94.57±0.07 
F3 6.47±0.18 0.123±0.004 6.91±0.02 82±1.81 7.23±0.75 8.75±0.05 1.76±0.0107 93.50±0.03 
F4 7.22±0.11 0.131±0.007 7.20±0.19 80±3.20 6.98±0.123 8.9±0.06 1.92±0.0102 92.70±0.01 
F5 6.77±0.71 0.148±0.003 7.10±0.11 94±2.12 8.64±0.65 6.57±0.21 2.21±0.0126 93.67±0.08 
F6 6.61±0.42 0.157±0.012 6.82±0.05 90±3.52 8.20±0.67 6.79±0.11 2.33±0.0234 97.34±0.01 
F7 6.82±0.17 0.143±0.015 7.19±0.14 93±1.43 9.64±0.42 6.13±0.36 1.71±0.0241 98.34±0.08 
F8 6.33±0.27 0.160±0.007 7.14±0.01 94±2.76 8.56±0.13 7.57±0.14 1.89±0.0114 97.90±0.01 
F9 7.02±0.20 0.156±0.017 7.02±0.09 96±1.05 11.46±0.46 6.68±0.27 1.82±0.0113 99.40±0.04 
F10 6.59±0.56 0.164±0.013 6.97±0.06 84±1.26 11.96±0.60 5.68±0.39 1.99±0.0103 99.23±0.07 
F11 6.88±0.19 0.162±0.002 6.87±0.12 92±2.74 10.11±0.24 4.6±0.09 2.13±0.0321 96.89±0.02 
F12 6.41±0.31 0.177±0.006 7.16±0.17 95±2.34 11.34±0.12 5.98±0.12 2.61±0.0248 93.79±0.08 
F13 7.07±0.16 0.162±0.012 7.12±0.10 95±2.87 12.64±0.45 5.46±0.38 1.96±0.0108 98.01±0.03 
F14 6.91±0.32 0.172±0.008 7.15±0.11 98±3.02 12.75±0.87 4.57±0.20 2.12±0.0101 99.78±0.01 
F15 7.09±0.51 0.169±0.011 7.08±0.19 79±1.38 13.57±0.20 4.8±0.70 2.18±0.0111 95.78±0.05 
F16 6.65±0.3 0.171±0.01 7.17±0.1 87±2.09 13.64±0.70 5.6±0.20 2.71±0.030 96.24±0.0 
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In vitro diffusion study 
In vitro drug release of the Sulfacetamide sodium ocusert 
was formulated by making 16 batches (F1 to F16). Various 
release kinetic model such as zero order, first order, Higuchi 
model and Korsemeyer-Peppas release model were studied 
for all formulations. All formulations were seen following 
zero order release kinetics out of which the best formulation 
F9 revealed better controlled release of drug content in-vitro 
(99.5%) within 12 hrs. is shown in figure 1. 
 
Table 5: In-vitro drug release profile of sulfacetamide sodium ocusert containing PVA, EC, HPMC K-15 (batch F9) 
Time (hrs) 0 1 2 3 4 5 6 7 8 9 10 11 12 
Cumulative 
%drug 
dissolved 
0 6.92 16.16 25.28 34.88 46.18 49.34 57.55 64.29 72.89 87.64 95.75 99.53 
 
 
 
Figure 1: Zero order release kinetics model of controlled release ocusert of Sulfacetamide sodium containing PVA, EC 
and HPMC (F9). 
Sterility studies   
 
 
 
Figure 2: Sterility test for Sulfacetamide sodium in soybean casein media 
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Figure 3: Sterility test for Sulfacetamide sodium in Fluid thioglycolate media 
 
There was no appearance of turbidity and hence no evidence 
of microbial growth when the formulation was incubated for 
not less than 14 days at 300°C to 350°C in case of fluid 
thioglycolate medium (Figure 2) and at 20°C to 25°C in case 
of soybean casein digest medium (Figure 3) the formulation 
being examined there for passed the test for sterility. 
CONCLUSION 
Ocular inserts of Sulfacetamide sodium were prepared 
successfully by solvent casting method using different 
polymers (PVA, HPMC and EC) in different combinations and 
proportions. Di-butyl-phthalate was used as plasticizer. 
Methyl-paraben and Propyl-paraben were used as 
preservatives and monobasic sodium phosphate was used as 
buffer. Resultant formulation F9 showed best in-vitro release 
of Sulfacetamide sodium.  We found PVA and HPMC were 
good film forming hydrophilic polymers and a promising 
agent for ocular delivery. EC was a satisfactory polymeric 
ingredient to fabricate the rate controlling membrane of the 
ocusert system. Di-butyl-phthalate enhanced the 
permeability of Sulfacetamide sodium and thus therapeutic 
levels of drug could be achieved.  
These ocuserts were smooth, flexible, and uniform in 
thickness and weight. The ocusert showed sustained release 
characteristics with a zero order of drug release; so 
prepared ocusert could be a promising delivery system for 
Sulfacetamide sodium with controlled drug release profile. 
Sterility studies was done and it was found no appearance of 
turbidity and hence no evidence of microbial growth. 
Overall, all the problems of poor bioavailability, frequent 
dosing and wastage of active ingredient were successfully 
dealt with developed ocular insert.  
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